Ketotifen

Category	Influenza Virus
CAS	34580-13-7
Description	Ketotifen is a cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators, used as self-medication for the temporary relief of itching of the eye due to allergic conjunctivitis (ophthalmic).

Quotation Now

Product Information

Synonyms	10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one,4,9-dihydro-4-(1-methyl-4-piper; 4-(1-Methyl-4-piperidinylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one;
IUPAC Name	2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
Molecular Weight	309.426
Molecular Formula	C19H19NOS
Canonical SMILES	CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
InChI	1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3
InChIKey	ZCVMWBYGMWKGHF-UHFFFAOYSA-N
Boiling Point	488.9°C at 760mmHg
Melting Point	152-153 °C
Flash Point	249.5°C
Purity	≥98%
Density	1.236g/cm3
Solubility	Soluble in DMSO
Appearance	Crystals (from ethyl acetate).
Application	Histamine receptor antagonists
Shelf Life	As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Storage	Store at -20 °C
Complexity	476
Exact Mass	309.11873540
In Vitro	Ketotifen (0-100 μM; 2 or 4 days) inhibits SARS-CoV-2 with an EC50 of 48.9 μM; and increases the percentage inhibition of SARS-CoV-2 to 79%, 83% and 93% when co-administers with 25, 50 and 100 μM Indomethacin, respectively. Ketotifen (0-50 μM; 24 h) has inhibitory activity against PR8, pH1N1 and H3N2 with EC50s of 5.9 μM, 33.7 μM and 48.5 μM, respectively; and exhibits relatively low cytotoxicity in MDCK cells (EC50=291 μM).
In Vivo	Ketotifen (80 mg/kg; i.g.; daily for 3 days) reduces end organ damage and mortality in mice infected with influenza virus. Ketotifen (0.4 mg/kg; i.p.; daily for 10 days) reduces encephalomyelitis (EAE) prevalence and severity. Animal Model: Female C57BL/6 mice (4-6 weeks; intranasal infection with 1×103 TCID50 of PR8 in 30 μL of DMEM) Dosage: 80 mg/kg Administration: i.g.; daily for 3 days Result: Reduced end organ damage and mortality in infected mice. Animal Model: Female C57BL/6 mice (5-6 weeks old; subcutaneously immunized with 150 μg of MOG35-55 peptide containing 4 mg/mL of Mycobacterium tuberculosis).
PSA	48.55000
Target	Histamine 1, SARS-CoV-2, Influenza virus
XLogP3-AA	3.2